• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants

byConstance Wu
February 4, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial involving extremely preterm infants, high dose erythropoietin did not reduce the risk of death or severe neurodevelopmental impairment at two years of age versus placebo.

2. This finding contradicts the results of previous studies involving different dosing regimens and more mature babies.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While advances in care have dramatically improved survival, preterm infants remain at high risk of functional and cognitive impairment. Erythropoietin is an erythropoietic agent that has also been shown to have neuroprotective effects in preclinical models and a meta-analysis of four randomized controlled trials. This placebo-controlled, double-blind trial was conducted to evaluate whether these benefits extended to extremely preterm infants, finding that there was no difference between groups in the primary outcome of death or severe neurodevelopmental impairment. Serious adverse events and common complications of prematurity occurred at similar rates in both groups. These results indicate the possibility that erythropoiesis-stimulating agents do indeed inhibit neurologic dysfunction but with a magnitude of effect that is overshadowed by the numerous unresponsive pathways in the most premature infants. While this study had a larger sample size than previous studies, it was limited by its reliance on testing at 2 years, as assessments at older ages are much more accurate predictors of neurodevelopmental outcomes. Another limitation was that infants with poorer prognoses who may have benefited the most from treatment were excluded from participation.

Click here to read the study in NEJM

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

#VisualAbstract: Extended Caffeine Does Not Reduce Hospitalization Time for Apnea in Moderately Preterm Infants

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

Tags: erythropoietinhematocritneurodevelopmentpreterm birth
Previous Post

Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer

Next Post

Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy

RelatedReports

New genetic link in pulmonary arterial hypertension holds therapeutic promise
Chronic Disease

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

June 2, 2025
#VisualAbstract: Extended Caffeine Does Not Reduce Hospitalization Time for Apnea in Moderately Preterm Infants
StudyGraphics

#VisualAbstract: Extended Caffeine Does Not Reduce Hospitalization Time for Apnea in Moderately Preterm Infants

May 21, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

May 10, 2025
Increased complications associated with emergent repeat cesarean
Obstetrics

Atosiban does not improve neonatal outcomes in threatened preterm births between 30-34 weeks

May 1, 2025
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Long term exposure to ambient fine particulate matter and incidence of stroke

#VisualAbstract: A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

#VisualAbstract: A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.